South Korea-based regenerative medicine company PharmaResearch Co., Ltd. (KOSDAQ: 214450), which develops medicines, medical devices, cosmetics and health supplements, said on Wednesday it has agreed to acquire US cosmetics manufacturer Cosmetic Group USA to strengthen its localisation strategy in North America.
PharmaResearch signed the agreement on 30 June as demand for its REJURAN Cosmetics brand increases in the United States following launches across Sephora and Amazon. Financial terms were not disclosed.
CG USA, based in California, provides OEM and ODM services covering product planning, formula development, manufacturing, filling, packaging and quality control. It operates an FDA-registered facility with a quality management system aligned with cGMP standards and has the capability to produce over-the-counter products.
PharmaResearch said the acquisition will secure a local production base, improving supply chain efficiency and responsiveness across manufacturing, logistics and distribution. The company, which currently supplies the US market with products made in Korea, aims to enhance supply stability in North America and accelerate its localisation strategy across the wider Americas. The brand is expanding through online and offline channels and is scheduled to enter Canada in the second half of the year.
Waters secures FDA clearance for BD BACTEC FXI Blood Culture System
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
ILC Dover adds Water for Injection (WFI) and custom chemical solutions to offerings
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Implantica submits final FDA response for RefluxStop PMA application
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AngioDynamics reports 24-month PRESERVE data showing durable NanoKnife outcomes in prostate cancer
Cepheid receives CE mark for IVDR‑compliant gastrointestinal PCR panel
Abingdon Health supports UK launch of LVOne stroke triage test
Fesarius Therapeutics reports publication of DermiSphere hDRT data
Shield Therapeutics announces Phase II trial initiation of ACCRUFeR in Japan for PAH
Johnson & Johnson secures EU approval for ETHICON 4000 surgical stapler
Implantica publishes large-scale RefluxStop study showing strong long-term safety outcomes